United Therapeutics Announces Commercial Launch Of The Remunity® Pump For Remodulin®
United Therapeutics Announces Commercial Launch Of The Remunity® Pump For Remodulin® News provided by Share this article Share this article SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it has launched commercial sales of the innovative Remunity ® Pump for Remodulin ® for patients with pulmonary arterial hypertension (PAH). "We are excited to bring to market the first subcutaneous pump designed specifically for PAH patients," said Beth Rhodes, Vice President, Global Supply Chain & Al...
Source: prnewswire.com